KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.98

Rivaroxaban in Peripheral Artery Disease After Revascularization: Worst Events and Net Outcomes in VOYAGER PAD.

Shea Hogan, Michael Szarek, E Sebastian Debus, Mark Nehler, Sonia S Anand, Manesh R Patel, Akos Ferenc Pap, Hsiaowei Deng, Sophie Hodge, Lloyd P Haskell, Eva Muehlhofer, Scott E Berkowitz, Rupert M Bauersachs, Marc P Bonaca

J Am Heart Assoc 14(21) e039752

PMID41128134
PMCIDPMC12684792
DOI10.1161/JAHA.124.039752
发表日期2025-10-23
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

BACKGROUND: VOYAGER PAD (Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities) demonstrated that antiplatelet therapy with rivaroxaban 2.5 mg twice daily compared with placebo reduced the first event in a composite end point in patients with peripheral artery disease after revascularization. The purpose of this analysis was to (1) evaluate whether rivaroxaban decreased the most severe events and (2) compare the harm and benefit of rivaroxaban on the same scale. METHODS: Two exploratory, hierarchical analyses of the primary efficacy composite outcome and one exploratory analysis of the net clinical benefit composite outcome were prespecified. The global rank method and the win ratio method ranked components of the composite outcome by clinical importance. The net clinical benefit included both efficacy and safety outcomes. RESULTS: The global rank method demonstrated that participants on rivaroxaban had fewer or later events than their placebo counterparts when events were compared in a hierarchical manner (primary ranking, P=0.0158). The win ratio approach demonstrated fewer or later fatal and nonfatal ischemic events in the rivaroxaban arm (win ratio, 1.16 [95% CI, 1.03-1.30]; P=0.0167). The net clinical benefit analysis revealed an overall beneficial effect of rivaroxaban when different efficacy and safety end points were included (P<0.001). CONCLUSIONS: Evaluation of the VOYAGER PAD primary outcome exploring ranking of components revealed that (1) rivaroxaban decreased the most severe ischemic events and (2) that across different efficacy and safety outcomes, results consistently supported a favorable benefit-risk profile. These results help inform shared decision making on the use of rivaroxaban 2.5 mg twice daily with daily antiplatelet therapy. REGISTRATION: URL: https://www.clinicaltrials.gov; unique identifier: NCT02504216.

KM 提取结果

1 个 Figure · 4 个 KM 面板

进入结果中心
KM Figure4 个面板

Figure 2

Figure 2. Net clinical benefit of the VOYAGER PAD efficacy and safety outcomes. Outcomes using various combined efficacy and safety end points at 3 years, comparing rivaroxaban to placebo. All analyses included myocardial infarction, ischemic stroke, acute limb ischemia, and major amputation. A , Included cardiovascular death and intracranial or fatal bleeding. B , Included cardiovascular death and TIMI major bleeding. C , Included all‐cause death and intracranial or fatal bleeding. D , Included all‐cause death and TIMI major bleeding. ASA indicates acetylsalicylic acid (aspirin); TIMI indicates thrombolysis in myocardial infarction; and VOYAGER PAD, Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities.

A

Net clinical benefit

Figure 2 · Panel A

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
B

Net clinical benefit

Figure 2 · Panel B

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel B 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
C

Net clinical benefit

Figure 2 · Panel C

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel C 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
D

Net clinical benefit

Figure 2 · Panel D

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel D 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. Win ratio exploratory, prespecified analysis of the VOYAGER PAD efficacy outcomes. Participants from the rivaroxaban arm were compared with participants in the placebo group at 3 years. The participant who experienced death first lost the event for his/her treatment arm. When death did not occur, the participant who experienced the first nonfatal end point lost the event. VOYAGER PAD indicates Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities.
非 KM Figure